The effect of hydroxychloroquine on engaging patients and parents to improve immuno-rheumatology center

Background: Complement is a biomarker known to be correlated with disease activity of systemic lupus erythematosus (SLE). However, it is not well-known how complement level changes after starting hydroxychloroquine (HCQ), one of the key drugs for the treatment of SLE, in patients with SLE. The aim of this study is to investigate the effect of HCQ on complement levels over a 12-month period in a large single center cohort of SLE in Japan.

Methods: We retrospectively collected the data of all 244 lupus patients treated with HCQ from the electrical medical record at St Luke’s International Hospital, Tokyo, Japan. We extracted the following parameters during the period between April 2008 and March 2018: baseline characteristics, complements levels (C3 and C4) at baseline1 month, 3 months, 6 months, 9 months, and 12 months after starting HCQ. Statistical analysis was performed using SPSS Statistics Version 21 (IBM Corp., Armonk, NY, USA). Mauchly’s sphericity test and analysis of variance with Greenhouse-Geisser correction was used.

Results: Total 244 patients on HCQ were included but 130 patients were excluded due to lack of sufficient data. The mean age of these 114 patients was 40.2 years and 108 patients (94.7%) were female.

The level of C4 (mg/dL) increased significantly (p<0.001) after starting HCQ. Especially, the level increased more dramatically from month 1 to month 3 compared to the other periods, and steadily increased over 6 months after initiating HCQ. In terms of C3, it showed the same trend. The number of flares of disease activity has been calculated.

Conclusions: The level of complements increases after initiating HCQ therapy in real-world patients with SLE in Japan. The effect tends to emerge 3 months after starting HCQ. We will show the data between disease activity and the elevation of complements.

Funding Source(s): None

Engaging patients and parents to improve mental health for youth with systemic lupus erythematosus

Background: Mental health conditions are common in youth with systemic lupus erythematosus (SLE), yet intervention strategies are understudied. We used a patient-engaged approach to investigate the mental health needs of youth with SLE.

Methods: An anonymous online survey examined beliefs and experiences with mental health for youth with SLE. Eligible youth ages 14–24 years had a diagnosis of SLE and reported specific treatment for the condition. Parents of youth 8–24 years meeting the above criteria were also eligible to participate. The survey was developed in collaboration with patient and parent advisors, the Childhood Arthritis and Rheumatology Research Alliance (CARRA), and the Patients, Advocates, and Rheumatology Teams Network for Research and Service (PARTNERS). Participants were recruited through the Lupus Foundation of America and CARRA clinics. We tabulated youth responses for i) self-reported prevalence of mental health problems, categorized into mutually exclusive clinician-diagnosed disorders and self-diagnosed symptoms, and ii) mean Likert ratings (0=low, 4=high) for the impact of disease related-factors on their mental health. We also compared

Funding Source(s): None

Abstract 91 Figure 1  C4 level. The level of C4 (mg/dL) increased significantly (p<0.001) after starting HCQ

Abstract 92

February 2019; 6[Suppl 1]:A1–A227
Results

102 respondents included 59 patients (58%) and 43 (42%) parents. Youth had a mean age of 20.9 (standard deviation, SD=3.4) years, and mean disease duration of 6.9 (SD 4.0) years. History of a mental health problem was reported by 21 youth (36%), of which 66% said that their rheumatologist was unaware. Clinician-diagnosed anxiety was reported by 19%, depression by 12%, and adjustment disorders by 19%; another 17%, 8% and 10% had self-reported symptoms of these disorders, respectively. Mean Likert ratings by youth indicated that disease aspects most impacting mental health were worry about disease impact on the future at 3.0 (SD 1.2), worry about having a flare at 2.9 (1.2), and worry about medication side effects at 2.8 (1.3). Youth and parents felt most comfortable discussing mental health concerns with rheumatologists and primary care providers, and least comfortable with social workers and school counselors (figure 1).

Conclusions

Youth with SLE have high rates of diagnosed and undiagnosed mental health problems, which are impacted by their disease. Mental health intervention strategies in rheumatology settings may improve mental health education, screening and treatment for these youth.

Funding Source(s): The Childhood Arthritis and Rheumatology Research Alliance

Abstract 92 Figure 1 Comparison of level of comfort with potential mental health providers among youth patients with SLE and parents. Results are shown for linear regression models comparing Likert scores among youth patients and parents, adjusted for disease duration and patient/parent-reported visual assessment score for disease-related health. *p<0.05, **p<0.01, ***p<0.001

Background

Organ damage may accumulate throughout life. The role of neuropsychiatric lupus manifestations on damage remains unknown. Cognitive dysfunction is present in 17%–66% of patients and an impact on damage accrual is suggested. We found a cognitive deficit association with the presence of anti-dsDNA/methyl-d-aspartate receptor (anti-dsDNA/NMDAR) and anti-ribosomal P proteins (anti-P), antibodies that have fluctuating titers with disease activity. Anti-P exerts neuropathogenic potential through recognition of neuronal surface antigens distributed in regions in memory, cognition and emotion. Anti-neuronal surface P antigen (NSPA), the anti-P target, is involved in neuronal excitatory transmission and mediates anti-P effects on memory dysfunction in mice models.

We investigated predictors associated to damage in a SLE cohort with a thorough neuropsychological and antineuronal antibodies baseline assessment, after 4.8 years of follow-up. We include data on a new class of antibodies recognizing NSPA and lacking anti-P reactivity.

Methods


Results

At baseline: mean age (37.0 years; SD 12.7), disease duration (7.2 years; SD 6.4), SLEDAI-2K score (7.4; SD 6.0) and SDI score (8.0; SD 1.3). Major depression (23%), cognitive deficit (18%) and both (3.4%). APS (9%). Antimalarials (84%) and cytotoxics (36%). Anti-dsDNA (49%), dsDNA/NMDAR (19%), anti-P (12%) and anti-NSPA (5%). After a mean follow-up of 4.8 (SD 2.0) years, 11.1% acquired new damage. Final SDI score was 1.0 (SD 1.6). In multivariate analysis baseline SDI, SLEDAI-2K and cytotoxics associated...